ScreenerHero

XRTX XORTX Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · xortx.com
1.745USD+0.87%Mkt Cap: 3.17M $P/E: —

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Pha…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.17M USD
Enterprise Value2.15M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-2.66M USD
Revenue/Share—
Last Price1.745 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)2.16
PEG—
EV/EBITDA-1.00
EV/Revenue—
P/S—
P/B1.16
EPS (TTM)-2.72
EPS (Forward)0.80
52W Range
1.6901% of range7.050
52W High7.050 USD
52W Low1.690 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-127.43%
ROA-98.99%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.77M USD
CapEx (TTM)55.22K USD
FCF Margin—
FCF Yield-81.42%
Net Debt-994.04K USD
Net Debt/EBITDA0.46
Balance Sheet
Debt/Equity0.02
Current Ratio3.59
Quick Ratio1.59
Book Value/Sh1.50 USD
Cash/Share0.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateApr 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.82M
Float1.79M
Insiders1.53%
Institutions0.01%
Short Interest
Short Ratio0.4d
Short % Float4.29%
Short % Out.4.23%
Shares Short76.75K
Short (prev mo.)18.86K
Technical
SMA 502.039 (-14.4%)
SMA 2002.280 (-23.4%)
Beta0.58
S&P 52W Chg15.78%
Avg Vol (30d)363.35K
Avg Vol (10d)39.65K
Technical Indicators
RSI (14)41.7
MACD-0.1098
MACD Signal-0.1035
MACD Hist.-0.0063
BB Upper2.353 USD
BB Middle1.887 USD
BB Lower1.422 USD
BB Width49.33%
ATR (14)0.1563 USD
Vol Ratio (20d)0.04x